{"entity":{"id":"nct05555732","kind":"trial","name":"Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)","aka":["TROPION-Lung07"],"tldr":"A phase 3 trial of Datopotamab deruxtecan, Pembrolizumab, Pemetrexed in non-small-cell lung cancer and small-cell lung cancer, run by Daiichi Sankyo, active and no longer recruiting.","summary":"Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07). ClinicalTrials.gov record last updated 2026-06-23: active not recruiting. Enrollment is planned at 1170 participants. Primary completion is estimated at 2029-05-11. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: Datopotamab Deruxtecan, Pembrolizumab, Pemetrexed, Carboplatin, Cisplatin. Registered primary measures: Progression-free Survival Based on Blinded Independent Central Review in All Randomized Participants; Progression-free Survival Based on Blinded Independent Central Review in All Randomized Participants who are TROP2 NMR positive; Overall Survival in All Randomized Participants.","status":"active","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT05555732","url":"https://clinicaltrials.gov/study/NCT05555732"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc"],"sections":[],"technologies":["adc","checkpoint-inhibitor","topoisomerase-inhibitors"],"targets":["trop2"],"drugs":["datopotamab-deruxtecan","pembrolizumab","pemetrexed","carboplatin","cisplatin"],"companies":["daiichi-sankyo"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["ClinicalTrials.gov record last updated 2026-06-23: active not recruiting. Enrollment is planned at 1170 participants. Primary completion is estimated at 2029-05-11. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications."],"nct":"NCT05555732","phase":"3","setting":"Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)","sponsor":"Daiichi Sankyo","participation":[{"nct":"NCT05555732","source":"https://clinicaltrials.gov/study/NCT05555732","fetchedAt":"2026-10-07T16:53:45.224Z","studySha256":"035ffa83995b920d5f9b2c6287dbf503360800dfa9b6e10e8fef81a7201a7a7c","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-06-23","leadSponsor":"Daiichi Sankyo","collaboratorCount":2,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":1170,"enrolmentType":"ESTIMATED","siteCount":260,"recruitingSiteCount":0,"countries":["Argentina","Australia","Austria","Belgium","Brazil","Canada","Chile","China","Czechia","France","Germany","Greece","Hong Kong","Hungary","Italy","Japan","Mexico","Netherlands","Poland","Portugal","Romania","South Korea","Spain","Switzerland","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom","United States"]}],"started":"2023-01-11","startedType":"actual","enrolled":1170,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05555732/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"target":[{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"datopotamab-deruxtecan","kind":"drug","name":"Datopotamab deruxtecan","route":"/drugs/datopotamab-deruxtecan/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"pemetrexed","kind":"drug","name":"Pemetrexed","route":"/drugs/pemetrexed/"}],"company":[{"id":"daiichi-sankyo","kind":"company","name":"Daiichi Sankyo","route":"/companies/daiichi-sankyo/"}]}}